Recombinant Human Breast Cancer Type 1 Susceptibility Protein (BRCA1) Protein (His)

Name: Recombinant Human Breast Cancer Type 1 Susceptibility Protein (BRCA1) Protein (His)
Brand: Beta LifeScience
SKU: BLC-08145P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Breast Cancer Type 1 Susceptibility Protein (BRCA1) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P38398
Target Symbol	BRCA1
Synonyms	BRCA 1; BRCA1; BRCA1 DNA repair associated; BRCA1/BRCA2 containing complex subunit 1; BRCA1/BRCA2-containing complex; subunit 1; BRCA1_HUMAN; BRCAI; BRCC 1; BRCC1; Breast and ovarian cancer susceptibility protein 1; Breast Cancer 1; Breast Cancer 1 Early Onset; Breast cancer type 1 susceptibility protein; BROVCA1; FANCS; IRIS; PNCA4; PPP1R53; Protein phosphatase 1 regulatory subunit 53; PSCP; RING finger protein 53; RNF53
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	CPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQCPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKDEVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYIELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQPSNNDLNTTEKRAAE
Expression Range	24-255aa
Protein Length	Partial
Mol. Weight	30.2kDa
Research Area	Epigenetics And Nuclear Signaling
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Required for FANCD2 targeting to sites of DNA damage. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8. Acts as a transcriptional activator.
Subcellular Location	Nucleus. Chromosome. Cytoplasm.; [Isoform 3]: Cytoplasm.; [Isoform 5]: Cytoplasm.
Database References	HGNC: 1100 OMIM: 113705 KEGG: hsa:672 STRING: 9606.ENSP00000418960 UniGene: PMID: 29126833 RAP80-BRCA1 complex foci formation is regulated by USP13.BRCA1 role in the DNA damage response. PMID: 28569838 RANK/RANKL were identified as crucial regulators for BRCA1 mutation-driven breast cancer. Current prevention strategies for BRCA1 mutation carriers are associated with wide-ranging risks; therefore, the search for alternative, non-invasive strategies is of paramount importance PMID: 29241686 Neither the patients tested nor the control subjects showed germline hypermethylation of the BRCA1 and BRCA2 promoter regions analyzed PMID: 29404838 Male carrying BRCA mutations have significantly lower QMAX than healthy men. BRCA1 patients have on average larger prostate glands and higher PSA than BRCA2 patients. PMID: 28577930 Results provide evidence that BRCA1 undergoes intronic premature polyadenylation (pPA) following large internal exons, and that N(6)-methyladenosine levels in this exon are reduced in pPA-activated breast cancer cells. PMID: 29362392 The combination of immunohistochemical expression of BRCA1, ER, PR, and HER-2/neu and clinicopathological details may be helpful in predicting the individuals more likely to carry BRCA1 mutations and thus selecting the candidate and family members for genetic screening for BRCA1 mutations. PMID: 29567881 methylation of BRCA1 was found to be significantly associated with tumor grade PMID: 30049201 The IRIS-driven metastatic mechanism results from IRIS-dependent suppression of phosphatase and tensin homolog (PTEN) transcription, which in turn perturbs the PI3K/AKT/GSK-3beta pathway leading to prolyl hydroxylase-independent HIF-1alpha stabilization and activation in a normoxic environment. PMID: 30254159 Both BRCA1 and BRCA2 mutations are associated with an increased risk for Prostate cancer(PC). BRCA2 in particular confers a more aggressive PC phenotype with a higher probability of locally advanced and metastatic disease, and should be considered a prognostic marker associated with poorer survival PMID: 29242595 Among BRCA mutation( BRCA1 or BRCA2) carriers, the mortality benefit of preventive mastectomy at age 25 is substantial, but the expected benefit declines rapidly with increasing age at surgery. PMID: 28914396 Significant increase in frequencies ofTP53 (rs1042522 G/C), BRCA1 (rs71361504 -/GTT, rs3092986T/C) genotypes and alleles in polycystic ovary patients compared to controls. PMID: 29860059 BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions. PMID: 30036938 this family depicts the intertwining cancer spectrum of with hereditary breast and ovarian cancer (HBOC) and familial pancreatic cancer (FPC) in BRCA1 families and raises awareness for the significance of considering pancreatic (head) adenocarcinoma (PAC)as differential phenotypic representation of the HBOC tumor spectrum. (Fig. 1a) and one pancreatic (head) adenocarcinoma (PAC) PMID: 28900739 High BRCA1 promoter methylation is linked to tumor grade and lymph node metastasis in breast cancer. PMID: 29970689 The present study demonstrates a clear protective effect of early first pregnancy on breast cancer risk in both BRCA1 and BRCA2 mutation carriers. PMID: 29116468 BRCA1 deficiency was recurrent in early-onset triple-negative breast cancer in Brazilian patients and associated with improved survival PMID: 29116469 Overall, 5152 oncogenetic tests were reviewed in the present study, of which 4452 had no a priori known familial mutation. The majority of participants (68.6%) were genotyped because of personal history of cancer; 20.6% were tested because of family history of cancer, and details for the remaining 10.7% were missing. Overall, 256/4452 (5.8%) carriers were detected, 141 BRCA1 and 115 BRCA2 mutation carriers. PMID: 29086229 CLDN3 expression and negative EGFR expression are associated with BRCA1 mutations in triple-negative breast cancers. PMID: 30142017 The present study aimed to clarify the clinicopathological features, including the level of p53 protein expression and BRCA mutations, of primary fallopian tube cancer (PFTC) in Japanese women. PMID: 29982601 Authors found that BRCA1/2 germline mutations in China exhibit distinct characteristics compared to those in Western populations. PMID: 29681614 analysis confirmed association between BRCA1 promoter methylation and breast cancer in Asia PMID: 29693332 A novel electrochemical DNA (E-DNA) biosensing strategy was designed and used for the detection of breast cancer susceptibility gene (BRCA-1). PMID: 29698810 Data suggest that targeting of breast cancer 1, early onset protein (BRCA1)-ribonucleotide reductase regulatory subunit M2 (RRM2) axis may represent a paradigm for therapeutic intervention in glioblastoma (GBM). PMID: 27845331 We show a strong association between Triple Negative Breast Cancer and mutations in BRCA1/2 genes and the poor outcome of these patients. The survival curve analysis showed that the presence of AKT1, TP53, KDR, KIT, BRCA1 and BRCA2 mutations is correlated with a poor prognosis. PMID: 29202330 Germline Mutation in the BRCA1 3'UTR Variant is associated with Breast Cancer. PMID: 29582646 Homozygous loss of function BRCA1 variant causes a Fanconi-anemia-like phenotype. PMID: 29133208 In summary, Nestin was strongly associated with germline BRCA1 related breast cancer, a basal-like phenotype, reduced survival, and stemness characteristics. PMID: 28439082 Homozygous nonsense mutations in the tumor suppressor gene BRCA1 is associated with breast and ovarian cancer. PMID: 29712865 Low BRCA1 expression is associated with radioresistance of glioma. PMID: 29286157 BRCA1 germ line mutation is associated with unilateral triple-negative breast cancer. PMID: 29514593 BRCA1 germ line mutation is associated with ovarian cancer. PMID: 29506471 High Promoter Methylation of BRCA1 gene is associated with Breast Cancer. PMID: 29480000 Ewing sarcoma cells display alterations in regulation of damage-induced transcription, accumulation of R-loops and increased replication stress; homologous recombination is impaired in Ewing sarcoma owing to an enriched interaction between BRCA1 and the elongating transcription machinery; also, a role is found for EWSR1 in the transcriptional response to damage, suppressing R-loops and promoting homologous recombination PMID: 29513652 Data indicate that BRCA1/2 mutations are not uncommon among selected Jordanian females with breast cancer. PMID: 29409476 Data show that male BRCA1/2 mutation carriers with breast and prostate cancer indicated a favorable 5-year survival. PMID: 29433453 findings provided the evidence that gBRCA1/2 mutation was not associated with survival in Chinese EOC patients, which possibly attributed to more than 37% of the patients without gross residual disease. Survival benefit of gBRCA1/2 mutation was prominent in ovarian cancer patients with gross residual disease. PMID: 29975922 BRCA1 SNP rs1799950 is associated with Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas. PMID: 29298688 The results of Ion PGM with OTG-snpcaller, a pipeline based on Torrent mapping alignment program and Genome Analysis Toolkit, from 75 clinical samples and 14 reference DNA samples were compared with Sanger sequencing for BRCA1/BRCA2. PMID: 28392550 Reduced BRCA1 expression was associated with ER and PR negative status resulting in Breast Carcinoma. PMID: 29286222 In this study, we used comprehensive multigene panels that included 35 known or suspected cancer susceptibility genes to examine BRCA1/2 mutation-negative Korean patients who had clinical features indicative of hereditary breast cancer PMID: 29338689 Pre-menopausal BRCA1/2 mutation carriers aged 30 to 47years chose screening, RRSO, or BS/DO. For those undergoing BS/DO, the delayed oophorectomy was recommended at age 40years for BRCA1 and age 45years for BRCA2 patients. PMID: 29735278 Based on a cumulative risk of 0.55% to age 35 for BRCA1 mutation carriers and of 0.56% to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects. PMID: 29793803 We demonstrate that homologous recombination deficiency (HRD)mutation signatures may offer clinically relevant information independently of BRCA1/2 mutation status and hope this work will guide the development of clinical trials PMID: 29246904 Overall, 65/648 (10%) study participants were BRCA1/2 mutation carriers. PMID: 30061222 BRCA1*R1699Q confers an intermediate risk for breast cancer and ovarian cancer. PMID: 28490613 patient-derived xenografts capture the molecular and phenotypic heterogeneity of triple-negative breast cancer . Here we show that PARP inhibition can have activity beyond germline BRCA1/2 altered tumors, causing regression in a variety of molecular subtypes. These models represent an opportunity for the discovery of rational combinations with targeted therapies and predictive biomarkers PMID: 29093017 BRCA methylation is rare in breast and ovarian carcinomas of BRCA germline mutation carriers, although the frequency of BRCA promoter methylation may be underestimated. This could have major implications for clinical practice, including referral for genetic testing and BRCAness analysis for treatment decision-making. PMID: 29891109 Carboplatin and talazoparib showed efficacy in DNA damage mutation carriers, but hematologic toxicity was more pronounced in gBRCA(gBRCA1/2) carriers. Carboplatin is best combined with intermittent talazoparib dosing differentiated by germline and somatic DNA damage mutation carriers PMID: 28790114 Putative BRCA1/2 reversion mutations can be detected by cfDNA sequencing analysis in patients with ovarian and breast cancer. Our findings warrant further investigation of cfDNA sequencing to identify putative BRCA1/2 reversion mutations and to aid the selection of patients for PARP inhibition therapy PMID: 28765325

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.